Journal article
Global protein profiling reveals anti-EGFR monoclonal antibody 806-modulated proteins in A431 tumor xenografts
ST Lee, H Ji, DW Greening, RWH Speirs, A Rigopoulos, V Pillay, C Murone, A Vitali, K Stühler, TG Johns, GA Corner, JM Mariadason, RJ Simpson, AM Scott
Growth Factors | INFORMA HEALTHCARE | Published : 2013
Abstract
An important mediator of tumorigenesis, the epidermal growth factor receptor (EGFR) is expressed in almost all non-transformed cell types, associated with tumor progression, angiogenesis and metastasis. The significance of the EGFR as a cancer therapeutic target is underscored by the clinical development of several different classes of EGFR antagonists, including monoclonal antibodies (mAb) and tyrosine kinase inhibitors. Extensive preclinical studies have demonstrated the anti-tumor effects of mAb806 against tumor xenografts overexpressing EGFR. EGF stimulation of A431 cells induces rapid tyrosine phosphorylation of intracellular signalling proteins which regulate cell proliferation and apo..
View full abstractGrants
Awarded by Australian Cancer Research Foundation
Funding Acknowledgements
Funding was provided by the Australian National Health and Medical Research Council under Program Grant #487922, and NHMRC Project Grant #234709. We acknowledge the NHMRC-funded Australian Proteomics Computational Facility (APCF) under Enabling Grant #381413. This work was supported, in part, by funds from the Operational Infrastructure Support Program provided by the Victorian Government, Australia. We acknowledge the Australian Cancer Research Foundation for providing funds to purchase the Orbitrap (TM) mass spectrometer. Andrew M. Scott and Terrance G. Johns are inventors on patents for mAb806.